Malignant Urinary System Neoplasm — Trials

Malignant Urinary System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

3,856 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 889
Recruiting: 468
Ph III recruiting: 52
Growth YoY: +14.4%
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (557)

clinicaltrialsPublishedShowing 851–900 of 3,856 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07445308	The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.	not yet recruiting	Phase 1 / Phase 2	120	Shenyang Sunshine Pharmaceutical Co., LTD.INDUSTRY	0	Mar 3, 2026	clinicaltrials
NCT07223541	Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma(LAG-BOOST)	recruiting	Phase 2	72	University of Oklahoma